Portfolio Design Labs LLC Purchases 4,794 Shares of Cencora, Inc. (NYSE:COR)

Portfolio Design Labs LLC boosted its stake in Cencora, Inc. (NYSE:COR - Free Report) by 76.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,032 shares of the company's stock after buying an additional 4,794 shares during the quarter. Portfolio Design Labs LLC's holdings in Cencora were worth $2,479,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Concord Wealth Partners bought a new position in shares of Cencora during the third quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC lifted its position in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after buying an additional 69 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of Cencora in the 3rd quarter worth approximately $41,000. Modus Advisors LLC bought a new position in shares of Cencora in the fourth quarter valued at approximately $54,000. Finally, Carolina Wealth Advisors LLC increased its position in shares of Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company's stock valued at $60,000 after acquiring an additional 209 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Performance

Shares of NYSE COR traded down $1.50 during mid-day trading on Friday, hitting $243.03. The company had a trading volume of 1,277,896 shares, compared to its average volume of 1,327,143. The stock's 50-day moving average price is $238.70 and its 200-day moving average price is $237.42. The company has a market capitalization of $46.97 billion, a price-to-earnings ratio of 34.57, a P/E/G ratio of 1.49 and a beta of 0.49. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $262.26.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, sell-side analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. Cencora's dividend payout ratio (DPR) is currently 31.29%.

Wall Street Analysts Forecast Growth

COR has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their target price on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price for the company. Finally, Barclays lifted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $277.90.

Insider Buying and Selling

In related news, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 73,187 shares of company stock worth $17,790,912. Corporate insiders own 10.80% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.